Global Epidemiology of Tuberculosis

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2014 Nov 1

PMID 25359550

Citations 84

Authors

Philippe Glaziou

Charalambos Sismanidis

Katherine Floyd

Mario Raviglione

Affiliations

Soon will be listed here.

Abstract

Despite the availability of effective chemotherapy, tuberculosis (TB) killed 1.3 million people in 2012. Alongside HIV, it remains a top cause of death from an infectious disease. Global targets for reductions in the epidemiological burden of TB have been set for 2015 and 2050 within the context of the Millennium Development Goals (MDGs) and by the Stop TB Partnership. Achieving these targets is the focus of national and international efforts in TB control, and showing whether or not they are achieved is of major importance to guide future and sustainable investments. This article provides a short overview of sources of data to estimate TB disease burden; presents estimates of TB incidence, prevalence, and mortality in 2012 and an assessment of progress toward the 2015 targets for reductions in these indicators based on trends since 1990 and projections up to 2015; analyzes trends in TB notifications and in the implementation of the Stop TB Strategy; and considers prospects for elimination of TB after 2015.

Citing Articles

Development of Enoyl Acyl Reductase (InhA) Inhibitors: A Mini-Review.

Tailor N, Deswal G, Guarve K, Singh Grewal A Mini Rev Med Chem. 2024; 25(3):219-233.

PMID: 39301902 DOI: 10.2174/0113895575309785240902102421.

Impact of Isoniazid Preventive Therapy on Tuberculosis Incidence and Predictors of Tuberculosis Among People Living With HIV/AIDS at Debre Tabor General Hospital, Northwest Ethiopia.

Nigussie K, Gebeye E, Kifle Z, Tadesse T, Birarra M Tuberc Res Treat. 2024; 2024:9741157.

PMID: 39234419 PMC: 11371443. DOI: 10.1155/2024/9741157.

Bayesian estimation of the time-varying reproduction number for pulmonary tuberculosis in Iran: A registry-based study from 2018 to 2022 using new smear-positive cases.

Rastegar M, Nazar E, Nasehi M, Sharafi S, Fakoor V, Shakeri M Infect Dis Model. 2024; 9(3):963-974.

PMID: 38873589 PMC: 11169078. DOI: 10.1016/j.idm.2024.05.003.

Advancements in Artificial Intelligence for the Diagnosis of Multidrug Resistance and Extensively Drug-Resistant Tuberculosis: A Comprehensive Review.

K S, Parivakkam Mani A, S G, Yadav S Cureus. 2024; 16(5):e60280.

PMID: 38872656 PMC: 11173349. DOI: 10.7759/cureus.60280.

Rising role of 3D-printing in delivery of therapeutics for infectious disease.

Kyser A, Fotouh B, Mahmoud M, Frieboes H J Control Release. 2024; 366:349-365.

PMID: 38182058 PMC: 10923108. DOI: 10.1016/j.jconrel.2023.12.051.

References

Comas I, Coscolla M, Luo T, Borrell S, Holt K, Kato-Maeda M . Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013; 45(10):1176-82. PMC: 3800747. DOI: 10.1038/ng.2744. View

Grimwade K, Sturm A, Nunn A, Mbatha D, Zungu D, Gilks C . Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS. 2005; 19(2):163-8. DOI: 10.1097/00002030-200501280-00008. View

Meintjes G, Schoeman H, Morroni C, Wilson D, Maartens G . Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC Infect Dis. 2008; 8:72. PMC: 2413241. DOI: 10.1186/1471-2334-8-72. View

Wells C, Cegielski J, Nelson L, Laserson K, Holtz T, Finlay A . HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007; 196 Suppl 1:S86-107. DOI: 10.1086/518665. View

Bierrenbach A, Stevens A, Gomes A, Ferreira Noronha E, Glatt R, Carvalho C . [Impact on tuberculosis incidence rates of removal of repeat notification records]. Rev Saude Publica. 2007; 41 Suppl 1:67-76. DOI: 10.1590/s0034-89102007000800010. View

Pantoja A, Floyd K, Unnikrishnan K, Jitendra R, Padma M, Lal S . Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients. Int J Tuberc Lung Dis. 2009; 13(6):698-704. View

Diacon A, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald P . 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012; 380(9846):986-93. DOI: 10.1016/S0140-6736(12)61080-0. View

Raviglione M, Pio A . Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet. 2002; 359(9308):775-80. DOI: 10.1016/s0140-6736(02)07880-7. View

Churchyard G, Scano F, Grant A, Chaisson R . Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis. 2007; 196 Suppl 1:S52-62. DOI: 10.1086/518662. View

10.

Borgdorff M, Glynn J, Vynnycky E . Using capture-recapture methods to study recent transmission of tuberculosis. Int J Epidemiol. 2004; 33(4):905-6. DOI: 10.1093/ije/dyh109. View

11.

Dye C, Fengzeng Z, Scheele S, Williams B . Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol. 2000; 29(3):558-64. View

12.

Sterling T . New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med. 2008; 29(5):532-41. DOI: 10.1055/s-0028-1085704. View

13.

Korenromp E, Glaziou P, Fitzpatrick C, Floyd K, Hosseini M, Raviglione M . Implementing the global plan to stop TB, 2011-2015--optimizing allocations and the Global Fund's contribution: a scenario projections study. PLoS One. 2012; 7(6):e38816. PMC: 3377722. DOI: 10.1371/journal.pone.0038816. View

14.

Ly L, McMurray D . Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines. 2008; 7(5):635-50. DOI: 10.1586/14760584.7.5.635. View

15.

Zignol M, Van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K . Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ. 2012; 90(2):111-119D. PMC: 3302554. DOI: 10.2471/BLT.11.092585. View

16.

Shilova M, Dye C . The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond B Biol Sci. 2001; 356(1411):1069-75. PMC: 1088501. DOI: 10.1098/rstb.2001.0895. View

17.

Corbett E, Charalambous S, Moloi V, Fielding K, Grant A, Dye C . Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med. 2004; 170(6):673-9. DOI: 10.1164/rccm.200405-590OC. View

18.

Dye C, Bassili A, Bierrenbach A, Broekmans J, Chadha V, Glaziou P . Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis. 2008; 8(4):233-43. DOI: 10.1016/S1473-3099(07)70291-8. View

19.

Botha E, Den Boon S, Lawrence K, Reuter H, Verver S, Lombard C . From suspect to patient: tuberculosis diagnosis and treatment initiation in health facilities in South Africa. Int J Tuberc Lung Dis. 2008; 12(8):936-41. View

20.

Enarson D, Grzybowski S . Incidence of active tuberculosis in the native population of Canada. CMAJ. 1986; 134(10):1149-52. PMC: 1491042. View